Instruction for use: Dexaven
I want this, give me price
Active substance: Dexamethasone
ATX Code H02AB02 Dexamethasone
Pharmacological group
Glucocorticosteroid
The nosological classification (ICD-10)
C81 Hodgkin's disease [lymphogranulomatosis]
Paltauf-Sternberg disease, The generalized form of Hodgkin's disease, Lymphogranulomatosis, Hodgkin's disease, Hodgkin's lymphoma, Hodgkin's malignant lymphoma, Hodgkin's lymphoma, Lymphoproliferative diseases, Reticulosis fibromyaloid, Pelya-Ebstein fever
C85 Other and unspecified types of non-Hodgkin's lymphoma
Lymphoma of mixed type, Lymphomas from cells of the mantle zone, Malignant lymphoma, Lymphoma non-Hodgkin's disease, Lymphocytic lymphoma
C91.0 Acute lymphoblastic leukemia
Recurrence of acute leukemia, Blast Crisis, Lymphoblastic leukemia, Lymphoid blast crisis, Acute lymphoblastic leukemia, Acute lymphoblastic leukemia in adults and children, Acute lymphoblastic leukemia in children, Acute lymphatic leukemia
C91.1 Chronic lymphocytic leukemia
Chronic lymphatic leukemia with tumor-like growths, B-cell CLL, B-cell chronic lymphocytic leukemia, Chronic granulocyte leukemia, Chronic leukemia, Chronic lymphoblastic leukemia, Chronic B-cell lymphocytic leukemia
D59 Acquired hemolytic anemia
Hemolytic anemia, Microangiopathic anemia, Acute hemolytic anemia
D69.3 Idiopathic thrombocytopenic purpura
Werlhof's disease, Idiopathic autoimmune thrombocytopenia, Idiopathic thrombocytopenic purpura of adults, Idiopathic thrombocytopenic purpura in adults, Immune idiopathic thrombocytopenic purpura, Immune thrombocytopenia, Bleeding in patients with thrombocytopenic purpura, Evans Syndrome, Thrombocytopenic purpura, Thrombocytopenia of immune origin, Chronic idiopathic thrombocytopenic purpura, Essential thrombocytopenia, Autoimmune thrombocytopenic purpura in pregnancy, Posttransfusion purpura
D70 Agranulocytosis
Agranulocytosis is hereditary, Aleicia, Aleykocytosis, Agranulocytic angina, Angina agranulocytic, Primary cytopenia
E04.9 Non-toxic goiter, unspecified
The sporadic goiter, Non-toxic goiter
E06.1 Subacute thyroiditis
De Cherven's disease, De Kervena granulomatous goiter, Thyroiditis granulomatous giant cell
E27.1 Primary insufficiency of the adrenal cortex
Addison's Disease, Addisonism, Adrenocortical insufficiency, Hypofunction of the adrenal cortex, Collapse with Addison's Disease, Insufficiency of the adrenal cortex primary, Primary adrenocortical insufficiency, Primary adrenal insufficiency
E27.4 Other and unspecified adrenocortical insufficiency
Hypocorticism, Hypoaldosteronism, Adrenal insufficiency, Insufficiency of the adrenal cortex, Insufficiency of the adrenal cortex, Secondary adrenocortical insufficiency, Secondary adrenal insufficiency, Secondary insufficiency of the adrenal cortex, Temporary decrease in the function of the adrenal cortex, Dysfunction of the adrenal cortex
E27.8 Other specified disorders of the adrenal gland
E91 * Diagnosis of endocrine system diseases
Diagnosis of hypogalactia, Diagnosis of thyroid suppression, Diagnostic test of thyroid function, Diagnosis of hypothyroidism, Diagnosis of disorders of gonadotropic pituitary gland function, Thyroid scintigraphy test, Diagnostics of pheochromocytoma
J38.4 Laryngeal edema
Laryngeal edema of allergic genesis and on the background of irradiation, Acute non-infectious edema of the larynx
J44 Other chronic obstructive pulmonary disease
Allergic bronchitis, Bronchitis asthma, Asthmatic bronchitis, wheeze bronchitis, Bronchitis is an obstructive, bronchi disease, Shortness of sputum in acute and chronic respiratory diseases, Cough in inflammatory diseases of the lung and bronchus, Reversible airflow obstruction, Reversible obstructive airway disease, Obstructive bronchitis disease, Obstructive lung disease, Obstructive bronchitis, Spastic bronchitis, Chronic lung disease, Chronic nonspecific lung diseases, Chronic obstructive pulmonary disease, Chronic obstructive bronchitis, Chronic obstructive airway disease, Chronic obstructive pulmonary disease, Restrictive lung pathology
J45 Asthma
Asthma physical effort, status asthmaticus, Bronchial asthma, Asthma lung flow, Bronchial asthma with obstruction of sputum discharge, Bronchial asthma heavy currents, Bronchial asthma physical effort, hypersecretory asthma, Hormone-dependent form of bronchial asthma, Relief of asthma attacks in bronchial asthma, Non-allergic asthma, nocturnal asthma, Exacerbation of asthma, Asthma attacks, Endogenous forms of asthma, Night asthma, Cough with bronchial asthma
J46 Status asthmaticus
Asthmatic attack, status asthmaticus, Bronchospasm in bronchial asthma
J98.8.0 * Bronchospasm
Bronchospasm in bronchial asthma, Bronchospasm when exposed to an allergen, bronchospastic reactions, bronchospastic status, bronhospastichesky syndrome, Diseases accompanied by bronchospastic syndrome, reversible bronchospasm, spasmodic cough
L91.0 Keloid cicatrix
Hyperlusculation, Keloid, Keloid cicatrix, Kelloid scars
L92.0 Granuloma annular
Ring-shaped granuloma
L93.0 Discoid lupus erythematosus
Chronic discoid lupus erythematosus, Red discoid lupus, Discoid lupus, Discoid erythematosis
L98.9 Lesion of skin and subcutaneous tissue, unspecified
Adiponecrosis, Atonic leather, Diseases of the skin, Blister, Inflammatory disease of soft tissues, Inflammatory processes of epithelial tissues, Degenerative changes in the skin and mucous membranes, Degenerative changes in the skin and mucous membranes, Excess granulation, Thinning of the skin, Skin diseases, Maceration of the skin, Minor skin lesions, Surface crack and skin abrasion, Increased skin peeling, Skin lesion, Erosion of the skin, Lipedema, Local non-infectious processes of skin and soft tissues, Disturbance of skin structure, Dysfunction of the skin, Skin disorders
M05 Seropositive rheumatoid arthritis
Rheumatoid arthritis seropositive
M13.9 Arthritis, unspecified
Arthritis,Purulent arthritis (non-infectious), acute Arthritis,Pain in acute inflammatory diseases of the musculoskeletal system,Pain in chronic inflammatory diseases of the musculoskeletal system,The pain in osteoarthritis, Inflammation in osteoarthritis, Inflammatory arthropathy, Inflammatory and degenerative joint diseases, Inflammatory disease of the musculoskeletal system, Inflammatory joint disease, Inflammatory diseases of the musculoskeletal system, destructive arthritis, The disease of the musculoskeletal system, Diseases of the musculoskeletal system, Diseases of the musculoskeletal system and connective tissue, Infections musculoskeletal system, monoartrit, Non-infectious arthritis, rheumatic arthritis, Osteoarthritis, Acute inflammation of the musculoskeletal tissue, Acute inflammatory diseases of the musculoskeletal system, Acute inflammatory condition of the musculoskeletal system, Acute arthritis, Acute osteoarthritis, Post-traumatic osteoarthritis, Reactive arthritis, Chronic inflammatory diseases of the joints, Chronic arthritis, Chronic inflammatory arthritis, Chronic inflammation of the inner layer of the joint capsule, Chronic inflammation of the joint capsule,Chronic inflammatory disease of the joints, Exudative arthritis
M15-M19 Osteoarthritis
M35.9 Unspecified systemic involvement of connective tissue
Hyperplasia of connective tissue, Diffuse connective tissue disease, Collagen diseases, Collagenosis, Systemic diseases of connective tissue, Diffuse connective tissue diseases
M65.1 Other infectious tendosynovitis
Infections of soft tissues, Tendosinovit infectious
M71.9 Bursopathy, unspecified
Bursites, Alberta disease, Acute bursitis
M77.9 Other unspecified
Capsule, Periarthritis, Tendonitis, Tendopathy, Periarthropathy
M79.0 Other unspecified rheumatism
Degenerative rheumatic disease, Degenerative and rheumatic diseases of the tendons, Degenerative rheumatic diseases, Localized forms of rheumatism of soft tissues, Rheumatism, Rheumatism with a pronounced allergic component, Rheumatism of the articular and extraarticular, Rheumatic attack, Rheumatic complaints, Rheumatic diseases, Rheumatic disease of the spine, Relapses of rheumatism, Articular and extra-articular rheumatism, Articular and muscular rheumatism, Articular rheumatism, Articular syndrome with rheumatism, Chronic rheumatic pain, Chronic articular rheumatism, Rheumatoid diseases, Rheumatic diseases of the intervertebral disc
R57 Shock, not elsewhere classified
Obstructive shock
R57.0 Cardiogenic shock
cardiogenic shock
T78.2 Anaphylactic shock, unspecified
Anaphylactic shock, Anaphylactoid reaction, Anaphylactic shock, Anaphylactic reactions, Anaphylactic shock to drugs
T78.3 Angioedema
Edema Quincke, Laryngeal exacerbation with angioneurotic edema, Recurrent angioedema, Allergic edema, Recurrent swelling of Quincy
T78.4 Allergy, unspecified
Allergic reactions to insulin, Allergic reactions to insect stings, Allergic reactions similar to systemic lupus erythematosus, Allergic diseases, Allergic diseases of mucous membranes, Allergic diseases and conditions resulting from increased release of histamine, Allergic diseases of mucous membranes, Allergic symptoms, Allergic symptoms in the mucous membranes, Allergic reactions, Allergic reactions caused by insect bites, Allergic reactions, Allergic conditions, Allergic laryngeal edema, allergopathy, allergic conditions, Allergy, House dust allergy, Anaphylaxis, Cutaneous reactions to medications, Skin reaction to insect stings, Cosmetic allergy, Drug allergy, Acute allergic reaction, Laryngeal edema allergic genesis and background radiation, Food and drug allergy
T79.4 Traumatic shock
Hemorrhagic shock, Crush syndrome, hemorrhagic shock, postoperative shock, post-traumatic shock, traumatic shock, hemorrhagic shock and encephalopathy syndrome
T81.1 Shock during or after the procedure, not elsewhere classified
Operating shock, Postoperative shock, Operational shock
Composition and form of release
Solution for injection 1 ml
Dexamethasone sodium phosphate 4.37 mg
(Corresponding to 4 mg of dexamethasone phosphate)
Auxiliary substances: benzalkonium chloride; Disodium vercenate; Sodium sulfite; Sodium dihydrogen phosphate; Sodium hydrogen phosphate; water for injections
In ampoules of 1 and 2 ml; In a cardboard bundle 10 pcs.
pharmachologic effect
Pharmacological action - anti-inflammatory, anti-allergic, anti-shock.
Oppresses phospholipase A2, reduces the synthesis of PG (prostaglandins) and leukotrienes, isolates the macrophage chemotactic factor, reduces the migration of macrophages and lymphocytes to the inflammation focus, stabilizes the lysosome membranes, prevents the release of lysosomal enzymes.
Pharmacodynamics
Has anti-inflammatory properties: suppresses alteration, exudation and proliferation. Antiallergic activity is caused by blockade of release from sensitized mast cells and basophils of histamine and other biologically active substances, suppression of immunogenesis. It affects the water-salt metabolism (delays sodium ions and water in the body, increases the volume of plasma and hydrophilicity of tissues), increases blood pressure.
Indications
All types of shock (posttraumatic, anaphylactic, postoperative, cardiogenic), atopic bronchial asthma, asthmatic status, chronic obstructive bronchitis, strumectomy (prevention of complications), laryngeal and vocal cord edema, severe allergic reactions, rheumatoid arthritis in the exacerbation phase, connective tissue diseases, Addison-Birmer disease.
Contraindications
Hypersensitivity, active forms of tuberculosis, diabetes mellitus, systemic infections, arterial hypertension, acute psychosis, acute renal failure, osteoporosis, Cushing's syndrome, pregnancy.
pregnancy and lactation
Contraindicated during pregnancy.
Side effects
From the cardiovascular system and blood (blood, gemostaz): hypertension, thrombophlebitis, leukocytosis.
On the part of the gastrointestinal tract (gastrointestinal tract): exacerbation of peptic ulcer of the stomach and duodenum.
From the side of metabolism: electrolyte balance disorders, hypoproteinemia, secondary adrenocortical insufficiency, steroid diabetes.
From the skin: petechiae, skin atrophy, striae, ecchymosis.
Other: peripheral edema, activation of foci of infection, osteoporosis, increased excitability, psychosis.
Interaction
Barbiturates, phenytoin, rifampicin, gliamide lower the effect (accelerate metabolism). Weakens the action of insulin and oral antidiabetic drugs, reduces the concentration of salicylates in the blood, increases the likelihood of hypokalemia in the face of digitalis or diuretics (combined with caution).
Dosing and Administration
The dosage regimen is determined individually depending on the indications, the patient's condition and his reaction to therapy. In / in (intravenously) slowly struino or drip (for acute and urgent conditions), IM (intramuscularly), possibly intraarticular, intrasynovial and local (in pathological education) introduction. During the day, you can enter 4-20 mg 3-4 times. The duration of parenteral use is usually not more than 1 week, then switch to maintenance therapy with an oral form. In the acute period, with different diseases and at the beginning of therapy, higher doses are prescribed. When the effect is achieved, the dose is gradually reduced to a maintenance dose or until treatment is discontinued.
special instructions
Immediately before administration, the contents of the ampoule are diluted with isotonic sodium chloride solution or 5% glucose solution.
storage conditions
In the dark place at a temperature of 5-25 ° C.
Keep out of the reach of children.
Shelf life
2 years.
Do not use after the expiry date printed on the package.